Research Summary

The central aim of my lab’s research is to develop novel biomarkers to non-invasively measure oncogene activity in cancer to improve diagnosis and the assessment of drug pharmacodynamics. This is a highly interdisciplinary research program, and I recruit students and postdocs that generally have a specialized background (i.e. a strong training in organic chemistry or cell biology, but not both), and train them in the other areas required of a well round molecular imaging researcher. Our projects span all aspects of biomarker development, from discovery with “omic” technologies, to refinement of lead agents to improve bioactivity in vivo. The majority of our de novo radiotracer development focuses on small molecule organic chemistry, and our antibody radiotracer development programs involves new bioconjugation chemistry, and defining and exploiting the biological mechanisms that underwrite the aberrant expression of cell surface receptors in cancer.

Research Funding

  • March 1, 2021 - February 28, 2026 - Precision targeting of T cell cytotoxicity with PET , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA258297
  • July 1, 2021 - March 31, 2025 - Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01EB029429
  • April 20, 2021 - March 31, 2025 - New radiotracer development to study immune cell mobilization of granzyme proteolytic activity , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01AI161027
  • June 1, 2020 - May 31, 2023 - Detection of the glucocorticoid receptor with PET in treatment resistant castration resistant prostate cancer , Principal Investigator . Sponsor: Department of Defense Prostate Cancer Research Program, Sponsor Award ID: W81XWH-20-1-0354


St. Mary’s College of Maryland, MD, BA, 2001, Chemistry
The Scripps Research Institute, La Jolla, CA, PhD, 2007, Chemical Biology
Memorial Sloane Kettering Cancer Center, New York, NY, Postdoctoral, 2013, Molecular Imaging, Cancer Biology

Honors & Awards

  • 2005
    1st Place Presentation, TSRI Faculty-Student Retreat
  • 2007-2010
    R25T Fellowship, National Institutes of Health (administered via MSKCC)
  • 2011-2012
    Research Grant, Brain Tumor Center, MSKCC
  • 2012
    Pathway to Independence Award, NCI
  • 2012-2014
    Research Grant, Imaging and Radiation Sciences Bridge Program, MSKCC
  • 2013
    Poster Award, World Molecular Imaging Congress, Savannah, GA
  • 2013
    David H. Koch Young Investigator Award, Prostate Cancer Foundation

Selected Publications

  1. Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ. Theranostic targeting of CUB domain containing protein 1 (CDCP1) in multiple subtypes of bladder cancer. Clin Cancer Res. 2023 Jan 17.  View on PubMed
  2. Gonciarz RL, Sakhamuri S, Hooshdaran N, Kumar G, Kim H, Evans MJ, Renslo AR. Elevated labile iron in castration-resistant prostate cancer is targetable with ferrous iron-activatable antiandrogen therapy. Eur J Med Chem. 2023 Jan 14; 249:115110.  View on PubMed
  3. Tran VL, Bouleau A, Nozach H, Richard M, Chevaleyre C, Dubois S, Kereselidze D, Kuhnast B, Evans MJ, Specklin S, Truillet C. Impact of Radiolabeling Strategies on the Pharmacokinetics and Distribution of an Anti-PD-L1 PET Ligand. Mol Pharm. 2022 10 03; 19(10):3673-3680.  View on PubMed
  4. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075.  View on PubMed
  5. Agarwal S, Decavel-Bueff E, Wang YH, Qin H, Santos RD, Evans MJ, Sriram R. Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex. Front Oncol. 2022; 12:851192.  View on PubMed
  6. Jiang H, Muir RK, Gonciarz RL, Olshen AB, Yeh I, Hann BC, Zhao N, Wang YH, Behr SC, Korkola JE, Evans MJ, Collisson EA, Renslo AR. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. J Exp Med. 2022 04 04; 219(4).  View on PubMed
  7. Martinko AJ, Simonds EF, Prasad S, Ponce A, Bracken CJ, Wei J, Wang YH, Chow TL, Huang Z, Evans MJ, Wells JA, Hill ZB. Switchable assembly and function of antibody complexes in�vivo using a small molecule. Proc Natl Acad Sci U S A. 2022 03 01; 119(9).  View on PubMed
  8. Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4).  View on PubMed
  9. Kim H, Huang Y, Zhao N, Wang YH, Sakhamuri S, Chopra S, Hooshdaran N, Sriram R, Aggarwal R, Evans MJ. In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Mol Pharm. 2022 02 07; 19(2):704-709.  View on PubMed
  10. Wei J, Oh DY, Evans MJ. Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods Mol Biol. 2022; 2393:829-839.  View on PubMed
  11. Bouleau A, Nozach H, Dubois S, Kereselidze D, Chevaleyre C, Wang CI, Evans MJ, Lebon V, Maill?re B, Truillet C. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of 89Zr-Labeled Anti-PD-L1 Antibody Formats. J Nucl Med. 2022 08; 63(8):1259-1265.  View on PubMed
  12. Meher N, Seo K, Wang S, Bidkar AP, Fogarty M, Dhrona S, Huang X, Tang R, Blaha C, Evans MJ, Raleigh DR, Jun YW, VanBrocklin HF, Desai TA, Wilson DM, Ozawa T, Flavell RR. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen. ACS Appl Mater Interfaces. 2021 Nov 24; 13(46):54739-54752.  View on PubMed
  13. Zhao N, Bardine C, Louren?o AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Cent Sci. 2021 Oct 27; 7(10):1638-1649.  View on PubMed
  14. Tran VL, Lux F, Tournier N, Jego B, Ma?tre X, Anisorac M, Comtat C, Jan S, Selmeczi K, Evans MJ, Tillement O, Kuhnast B, Truillet C. Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque. Adv Healthc Mater. 2021 08; 10(16):e2100656.  View on PubMed
  15. Ivan de Kouchkovsky, Spencer Behr, Li Zhang, Adam Foye, Henry Vanbrocklin, Eric Jay Small, Felix Y Feng, Terence W. Friedlander, Patricia Li, Natalie Frey, Andy Chung, Austin Lui, Aishwarya Subramanian, Tammy J. Rodvelt, Brigid Barlesi, Michael Evans, Rahul Raj Aggarwal. Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):31-31.  View on PubMed
  16. Kalita M, Villanueva-Meyer J, Ohkawa Y, Kalyanaraman C, Chen K, Mohamed E, Parker MFL, Jacobson MP, Phillips JJ, Evans MJ, Wilson DM. Synthesis and Screening of a-Xylosides in Human Glioblastoma Cells. Mol Pharm. 2021 01 04; 18(1):451-460.  View on PubMed
  17. Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021 03 01; 27(5):1305-1315.  View on PubMed
  18. Zhao N, Huang Y, Wang YH, Muir RK, Chen YC, Wei J, Hooshdaran N, Viswanath P, Seo Y, Ruggero D, Renslo AR, Evans MJ. Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies. J Nucl Med. 2021 07 01; 62(7):949-955.  View on PubMed
  19. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Garrido-Ruiz D, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (�)-11C-YJH08 PET. J Nucl Med. 2021 05 10; 62(5):723-731.  View on PubMed
  20. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 12; 22(6):1553-1561.  View on PubMed

Go to UCSF Profiles, powered by CTSI